« Back to Record
Citation APA

Sternberg, C. N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D., & EORTC Genitourinary Tract Cancer Group, (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of oncology, 20(7), 1264-1269. doi:10.1093/annonc/mdn784


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/119812

Sternberg, C. N., Dumez, H., Van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G., Gil, T., Graham, J., Carpentier, P., Calabro, F., Collette, L., Lacombe, D., & EORTC Genitourinary Tract Cancer Group, (2009). Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of oncology, 20(7), 1264-1269. doi:10.1093/annonc/mdn784